ArticleEJHaem2026
Choroidal Leakage during Daratumumab Therapy: A Desensitization-Based Strategy for Treatment Continuation in Relapsed/Refractory Multiple Myeloma.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Daratumumab is widely used in relapsed/refractory multiple myeloma, but ocular adverse events are rare and not well-characterized. Case Presentation: A 68-year-old woman developed acute blurred vision during the second day of her first daratumumab infusion. Multimodal imaging, including fluorescein angiography, indocyanine green angiography, and optical coherence tomography (OCT), demonstrated bilateral choroidal leakage with subretinal fluid and choroidal vascular changes. Management and Outcome: Daratumumab was temporarily discontinued due to suspected drug-related ocular toxicity. Following complete symptom resolution, treatment was successfully reintroduced using a 12-step desensitization protocol with close monitoring. No recurrence of ocular symptoms was observed, and follow-up imaging showed regression of subretinal fluid. Conclusion: This case highlights a rare ocular complication associated with daratumumab and suggests that desensitization may enable safe continuation of therapy in selected patients with non-vision-threatening findings. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.